The Covid-19 vaccine developed by the China National Pharmaceutical Group (Sinopharm) has been approved for market, with conditions, and will be provided free to the national inoculation programme, Chinese officials said on Thursday.The vaccine, developed by Sinopharm subsidiary the Beijing Institute of Biological Products, has already been provided to high risk groups in China under an emergency use authorisation.China’s Sinopharm reports strong interim results for its Covid-19 vaccine…


READ  National security law: American firms review their Hong Kong future after Donald Trump fires starting gun on dismantling city’s trade privileges


Please enter your comment!
Please enter your name here